

**Supplementary Fig. S1.** Consort diagram.

Treatment episode (ep.) was defined from treatment initiation until discontinuation.

**Supplementary Table S1.** Univariable analysis for event-free survival.

		n.	%	p-value	HR	Lower 95% CI	Upper 95% CI	1-y EFS	2-y EFS	3-y EFS
Sex	<b>Male</b>	78	43.8	.	.	.	.	68%	57%	45%
	<b>Female</b>	384	48.9	0.309	1.14	0.89	1.45	64%	52%	41%
Year of episode	<b>&lt;2013</b>	195	47.2	0.000	1.00	0.00	0.00	71%	59%	49%
	<b>2014-2015</b>	161	55.3	0.000	1.62	1.32	2.00	57%	44%	33%
	<b>2016-2019</b>	106	40.8	0.023	1.32	1.04	1.68	63%	52%	40%
Age at episodes	<b>70+</b>	88	44.0	0.435	1.00	0.00	0.00	66%	54%	46%
	<b>50-69</b>	255	48.6	0.656	1.06	0.83	1.35	67%	53%	42%
	<b>&lt;50</b>	119	49.8	0.227	1.19	0.90	1.56	60%	51%	40%
Disease duration (y)	<b>1-4</b>	130	48.0	0.864	1.00	0.00	0.00	64%	53%	42%
	<b>4.01-10</b>	122	48.2	0.817	0.97	0.76	1.24	66%	52%	40%
	<b>10+</b>	210	47.7	0.592	0.94	0.76	1.17	64%	53%	43%
BMI (3 groups)	<b>18.5-24.9</b>	140	47.6	0.441	1.00	0.00	0.00	68%	55%	43%
	<b>25-34.9</b>	175	44.0	0.390	0.91	0.73	1.13	68%	58%	48%
	<b>≥35</b>	44	52.4	0.568	1.10	0.79	1.55	66%	47%	39%
Treatment line	<b>1</b>	166	45.6	0.018	1.00	0.00	0.00	70%	57%	45%
	<b>2</b>	101	42.3	0.900	0.98	0.77	1.26	66%	56%	49%
	<b>3</b>	82	51.3	0.074	1.27	0.98	1.66	62%	48%	37%
	<b>4</b>	56	57.1	0.008	1.50	1.11	2.04	57%	47%	30%
	<b>5+</b>	57	55.3	0.050	1.35	1.00	1.83	58%	42%	34%
All lines	<b>Tofacitinib</b>	61	43.9	.	.	.	.	61%	48%	43%
	<b>Etanercept</b>	153	58.0	0.412	1.13	0.84	1.53	57%	46%	35%
All lines	<b>Tofacitinib</b>	61	43.9	.	.	.	.	61%	48%	43%
	<b>Golimumab</b>	53	48.6	0.805	0.96	0.66	1.38	65%	50%	37%
All lines	<b>Tofacitinib</b>	61	43.9	.	.	.	.	61%	48%	43%
	<b>Tocilizumab</b>	130	40.0	0.006	0.65	0.48	0.88	73%	62%	53%
All lines	<b>Tofacitinib</b>	61	43.9	.	.	.	.	61%	48%	43%
	<b>Abatacept</b>	65	51.2	0.791	1.05	0.74	1.49	64%	47%	30%
Methotrexate	<b>No</b>	99	43.0	.	.	.	.	69%	57%	46%
	<b>Yes</b>	363	49.5	0.138	1.18	0.95	1.48	64%	51%	41%
Prednisone	<b>No</b>	195	46.2	.	.	.	.	68%	56%	45%
	<b>Yes</b>	275	50.7	0.036	1.22	1.01	1.46	61%	49%	38%

Supplementary Table S2. Univariable interaction analysis for event-free survival.

		n.	%	p-value	HR	Lower 95% CI	Upper 95% CI	1-y EFS	2-y EFS	3-y EFS
First line	<b>Tofacitinib</b>	9	29.0	.	.	.	.	79%	70%	59%
	<b>Etanercept</b>	104	58.1	0.033	2.10	1.06	4.14	60%	47%	34%
First line	<b>Tofacitinib</b>	9	29.0	.	.	.	.	79%	70%	59%
	<b>Golimumab</b>	434	49.0	.	.	.	.	.	.	.
First line	<b>Tofacitinib</b>	9	29.0	.	.	.	.	79%	70%	59%
	<b>Tocilizumab</b>	26	30.2	0.805	0.91	0.42	1.95	80%	71%	63%
First line	<b>Tofacitinib</b>	9	29.0	.	.	.	.	79%	70%	59%
	<b>Abatacept</b>	8	40.0	0.482	1.41	0.54	3.65	75%	57%	46%
Second line	<b>Tofacitinib</b>	10	35.7	.	.	.	.	73%	53%	53%
	<b>Etanercept</b>	26	53.1	0.333	1.44	0.69	2.99	51%	49%	44%
Second line	<b>Tofacitinib</b>	10	35.7	.	.	.	.	73%	53%	53%
	<b>Golimumab</b>	10	58.8	0.139	1.94	0.81	4.68	43%	32%	22%
Second line	<b>Tofacitinib</b>	10	35.7	.	.	.	.	73%	53%	53%
	<b>Tocilizumab</b>	44	37.6	0.615	0.84	0.42	1.67	72%	63%	55%
Second line	<b>Tofacitinib</b>	10	35.7	.	.	.	.	73%	53%	53%
	<b>Abatacept</b>	11	39.3	0.776	1.13	0.48	2.67	73%	46%	39%
Third+ line	<b>Tofacitinib</b>	42	52.5	.	.	.	.	48%	36%	32%
	<b>Etanercept</b>	23	63.9	0.832	1.06	0.63	1.76	52%	40%	27%
Third+ line	<b>Tofacitinib</b>	42	52.5	.	.	.	.	48%	36%	32%
	<b>Golimumab</b>	24	54.5	0.583	0.87	0.53	1.44	58%	40%	27%
Third+ line	<b>Tofacitinib</b>	42	52.5	.	.	.	.	48%	36%	32%
	<b>Tocilizumab</b>	60	49.2	0.006	0.57	0.38	0.85	69%	55%	46%
Third+ line	<b>Tofacitinib</b>	42	52.5	.	.	.	.	48%	36%	32%
	<b>Abatacept</b>	46	58.2	0.484	0.86	0.57	1.31	58%	44%	23%
Etanercept_Methotrexate	<b>No</b>	30	54.5	.	.	.	.	54%	49%	37%
	<b>Etanercept &amp; Methotrexate</b>	123	58.9	0.928	1.02	0.68	1.52	58%	46%	35%
Golimumab_Methotrexate	<b>No</b>	12	52.2	.	.	.	.	61%	41%	34%
	<b>Golimumab &amp; Methotrexate</b>	41	47.7	0.664	0.87	0.46	1.65	66%	53%	39%
Tocilizumab_Methotrexate	<b>No</b>	27	32.9	.	.	.	.	81%	66%	61%
	<b>Tocilizumab &amp; Methotrexate</b>	103	42.4	0.137	1.38	0.90	2.11	70%	61%	51%
Abatacept_Methotrexate	<b>No</b>	18	50.0	.	.	.	.	75%	62%	34%
	<b>Abatacept &amp; Methotrexate</b>	47	51.6	0.251	1.38	0.80	2.38	60%	40%	28%
Tofacitinib_Methotrexate	<b>No</b>	12	35.3	.	.	.	.	62%	49%	49%
	<b>Tofacitinib &amp; Methotrexate</b>	49	46.7	0.517	1.23	0.66	2.32	60%	48%	41%
Prednisone_Tofacitinib	<b>No</b>	22	37.3	.	.	.	.	67%	59%	52%
	<b>Prednisone_Tofacitinib</b>	40	50.0	0.067	1.63	0.97	2.74	55%	40%	33%
Prednisone_Etanercept	<b>No</b>	71	55.9	.	.	.	.	62%	47%	36%
	<b>Prednisone_Etanercept</b>	82	59.9	0.405	1.15	0.83	1.57	53%	45%	34%
Prednisone_Golimumab	<b>No</b>	26	60.5	.	.	.	.	66%	50%	26%
	<b>Prednisone_Golimumab</b>	27	40.9	0.246	0.73	0.42	1.25	63%	50%	47%
Prednisone_Tocilizumab	<b>No</b>	52	35.6	.	.	.	.	77%	66%	59%
	<b>Prednisone_Tocilizumab</b>	85	47.5	0.022	1.50	1.06	2.12	68%	55%	45%
Prednisone_Abatacept	<b>No</b>	24	51.1	.	.	.	.	63%	47%	35%
	<b>Prednisone_Abatacept</b>	41	51.3	0.931	1.02	0.62	1.69	64%	47%	28%